ArticleJournal of cheminformatics2025
Visualising lead optimisation series using reduced graphs.
Article in Journal of cheminformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The typical way in which lead optimisation (LO) series are represented in the medicinal chemistry literature is as Markush structures and associated R-group tables. The Markush structure shows a central core or molecular scaffold that is common to the series with R groups that indicate the points of variability that have been explored in the series. The associated R-group table shows the substituent combinations that exist in individual molecules in the series together with properties of those compounds. This format provides an intuitive way of visualising any structure-activity relationship (SAR) that is present. Automated approaches that attempt to reproduce this well understood format, such as the SAR map, are based on maximum common substructure approaches and do not take account of small changes that may be made to the core structure itself or of the situation where more than one core exists in the data. Here we describe an automated approach to represent LO series that is based on reduced graph descriptions of molecules. A publicly available LO dataset from a drug discovery programme at GSK is analysed to show how the method can group together compounds from the same series even when there are small substructural differences within the core of the series while also being able to identify different related compound series. The resulting visualisation is useful in identifying areas where series are under explored and for mapping design ideas onto the current dataset. The code to generate the visualisations is released into the public domain to promote further research in this area.Scientific contribution: We describe a software tool for analysing lead optimisation series using reduced graph representations of molecules. The representation allows compounds that have similar but not identical chemical scaffolds to be grouped together and is, therefore, an advance on methods that are based on the more traditional Markush structure and SAR tables. The software is a useful addition to the med chem toolbox as it can provide a holistic view of lead optimisation data by representing what might otherwise be seen as separate series as a single series of compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.